Evidence map›Paper›PMID 42115474›Full record

ReviewInternational journal of clinical oncology2026

Targeting regulatory T cells in gastrointestinal cancers: current status and future perspectives.

Koichi Jinushi, Takuro Saito, Yuichiro Doki

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Koichi JinushiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan.
Takuro SaitoDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan. tsaito@gesurg.med.osaka-u.ac.jp.ORCID http://orcid.org/0000-0002-1733-5064
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although immune checkpoint inhibitors (ICIs) have revolutionized the gastrointestinal cancer treatment landscape, offering durable clinical benefits in a subset of patients, their efficacy remains limited to this subset of patients, underscoring the urgent need to elucidate the mechanisms underlying immune resistance and develop novel therapeutic strategies. Increasing evidence indicates that the immunosuppressive tumor immune microenvironment (TIME) is a major obstacle to effective antitumor immunity, with regulatory T cells (Tregs) emerging as the central cellular mediators of this process. Tumor-infiltrating Tregs possess potent immunosuppressive functions and suppress cytotoxic CD8

Indexed as

Gastrointestinal cancersImmune checkpoint inhibitorsRegulatory T cellsTreg-targeted immunotherapyTumor immune microenvironment

Identifiers

PMID42115474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.